Andrew Holman

Chief Executive Officer & Co-founder

Inmedix Inc and Inmedix UK Ltd

Andrew Holman

Andrew J. Holman, M.D., is a clinical rheumatologist, CEO and Co-founder of Inmedix, Inc. in Seattle and its subsidiary, Inmedix UK, Ltd. He established Inmedix to validate and commercialize autonomic nervous system (ANS) diagnostics and therapeutics to enhance immunosuppressive outcomes for patients with autoimmune diseases. He trained at the University of Washington (rheumatology fellowship), Presbyterian-St. Luke’s Medical Center (internal medicine residency), the University of Missouri-Columbia (M.D.) and Bowdoin College (A.B., Chemistry). Currently, he is also a Clinical Associate Professor Medicine at the University of Washington. His research identified the role of ANS assessment as a predictor of immunosuppressive treatment outcomes in patients with autoimmune diseases as well as how to enhance those outcomes through adjunctive ANS therapeutics. He discovered the role of dopamine agonists in the treatment of fibromyalgia and elucidated the dysautonomic effects of positional cervical cord compression (PC3) in humans with widespread pain.

Follow Andrew Holman' at upcoming/ongoing conferences at gtcbio:

Inflammatory & Immunological Biomarkers